Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:03:28.592Z.
Calculation as of: 2026-10-06T19:03:28.592Z.
Quote observation: 2026-10-06T19:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e88a9ce363f502b6754b19b8a4115a17c58c771a6bc05fe10e5aff55a47e2c9d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$14.05M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.20M
EBITDA Yield
N/A
TTM Avg
0.87%
3Y Avg
0.87%
5Y Avg
0.87%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sintx Technologies, Inc. (SINT) | $13.99M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.05M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.92M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.69M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | 0.87% | 0.87% | 0.87% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.89M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.08M | N/A | N/A | N/A | N/A |
| Jin Medical International Ltd. (ZJYL)vs › | $15.03M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
